19-28z t cells
Cell therapyexperimental
Clinical trial activity
5 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Apr 1, 2013 (NCT01840566)
Timeline
Indications
Studied for
- Glomerular Basement Membrane · Early Phase 1
- Leukemia · Phase 1
- Leukemia, Lymphoid · Phase 1
- Leukemia, Myelogenous, Chronic, BCR-ABL Positive · Phase 1
- Leukemia, Myeloid, Chronic, Atypical, BCR-ABL Negative · Phase 1
- Lymphoma · Phase 1
- Lymphoma, B-Cell · Phase 1
- Lymphoma, Follicular · Phase 2
- Lymphoma, Large B-Cell, Diffuse · Early Phase 1
- Lymphoma, Large-Cell, Immunoblastic · Early Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Neoplasms, Germ Cell and Embryonal · Early Phase 1
- Precursor B-Cell Lymphoblastic Leukemia-Lymphoma · Phase 1
- Precursor Cell Lymphoblastic Leukemia-Lymphoma · Phase 2
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 19-28z t cells
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06287528 | Phase 1 | Feb 23, 2024 | Memorial Sloan-Kettering Cancer Center |
| NCT05745181 | Phase 2 | Feb 1, 2023 | Xuzhou Medical University |
| NCT04512716 | Early Phase 1 (Phase 1) | Feb 2, 2021 | Actinium Pharmaceuticals, Memorial Sloan-Kettering Cancer Center |
| NCT04556266 | Phase 1 | Sep 14, 2020 | Memorial Sloan-Kettering Cancer Center |
| NCT01840566 | Phase 1 | Apr 1, 2013 | Cornell University |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 3 | 3 | 1 | 2020 |
| Actinium Pharmaceuticals | For profit | 1 | 0 | 1 | 2021 |
| Cornell University | Academic/Hospital | 1 | 1 | 1 | 2013 |
| Xuzhou Medical University | Academic/Hospital | 1 | 1 | 1 | 2023 |
4 organizations
Page 1 / 1